Skip to main content
. Author manuscript; available in PMC: 2012 Jul 15.
Published in final edited form as: J Immunol. 2011 Jun 15;187(2):1023–1030. doi: 10.4049/jimmunol.1004195

Figure 6. Stronger T cell reactivity to CM in patients with CAV.

Figure 6

A. Representative IFNγ ELISPOT wells in which PBMCs obtained from one patient without CAV (no CAV, top row) and one with CAV (bottom row) were stimulated with medium alone or 3 different pairs of CM-derived peptides. PHA served as a positive control. Numbers above each well are the spots detected. B. The prevalence of T cell reactivity to CM as defined by >10 IFNγ producers per 500,000 PBMCs in response to at least one peptide is shown for 18 patients with CAV and 13 patients without CAV (*p<0.05). C. Peptide mapping of PBMCs from CAV patients (left) and nCAV patients (right). Each color represents the responses of a different patient.